Main Page Content

This section is a source of information for health care providers to guide them in their clinical practice regarding the Universal Influenza Immunization Program (UIIP).

The Health Protection and Promotion Act 1990 (HPPA), R.S.O., 1990, outlines the requirements for physicians, practitioners, laboratories, and institutions to report any suspect or confirmed influenza cases to the Medical Officer of Health. This information is collected under Regulation 569 of the HPPA.  Influenza is to be reported by the next working day. If the individual presents with a novel or emerging respiratory infection, please report immediately to the Medical Officer of Health.

General information regarding Ontario’s influenza immunization program:

Information for Windsor-Essex County providers who administer influenza vaccines:

Adverse Events Following Immunization (AEFIs):

Health Care Provider Qs & As:

Information regarding the use of cell culture-based influenza vaccine (Flucelvax Quad) in pregnancy

  • Pregnant women are recognized as a priority group for influenza vaccination, as influenza infection in pregnancy increases the woman’s risk of hospitalization and other serious complications, as well as the baby’s risk of adverse neonatal outcomes. Vaccination of pregnant women also helps protect the baby from influenza in the first few months of life. 
  • Influenza vaccination in pregnancy is a safe and effective method for protecting pregnant women and their babies from influenza.   
  • The National Advisory Committee on Immunization (NACI) recommends offering any age-appropriate inactivated influenza vaccine product to all pregnant women, at any stage of pregnancy. This recommendation has been in place for over a decade in Canada and is considered the standard of care for pregnant women. 
  • Flucelvax® Quad was licenced for use in Canada in November 2019. Mammalian cell culture-based inactivated influenza vaccines have been used in other jurisdictions for over a decade. 
  • The NACI Supplemental Statement: Mammalian Cell Culture-Based Influenza Vaccines recommends that Flucelvax® Quad be considered among the quadrivalent inactivated influenza vaccine products offered to adults and children ≥ 9 years of age. NACI has advised that this recommendation was intended to apply to pregnant women (personal communication, NACI). Thus, as with other inactivated influenza vaccines, Flucelvax® Quad can be offered to pregnant women. 
  • Advisory Committee Statement (ASC): Supplemental Statement: Mammalian Cell Culture-Based Influenza Vaccines

Diagnostic Testing Updates:

  • Public Health Ontario Laboratory: Influenza testing with nasopharyngeal swab
  • Public Health Ontario Laboratory: Labstract (October 2020) - Respiratory Virus Testing Update

Treatment Updates:

Influenza Immunization Awareness Posters:

  • Browse a list of downloadable immunization posters from Immunize Canada, available in English and French.
Related Content: 
Last modified: 
Monday, June 27, 2022 - 3:26pm